RATIONALE: Mutations in vascular endothelial growth factor (VEGF) receptor-3 (VEGFR3 or FLT4) cause Milroy disease, an autosomal dominant condition that presents with congenital lymphedema. Mutations in VEGFR3 are identified in only 70% of patients with classic Milroy disease, suggesting genetic heterogeneity. OBJECTIVE: To investigate the underlying cause in patients with clinical signs resembling Milroy disease in whom sequencing of the coding region of VEGFR3 did not reveal any pathogenic variation. METHODS AND RESULTS: Exome sequencing of 5 such patients was performed, and a novel frameshift variant, c.571_572insTT in VEGFC, a ligand for VEGFR3, was identified in 1 proband. The variant cosegregated with the affected status in the family. An assay to assess the biological function of VEGFC activity in vivo, by expressing human VEGFC in the zebrafish floorplate was established. Forced expression of wild-type human VEGFC in the floorplate of zebrafish embryos leads to excessive sprouting in neighboring vessels. However, when overexpressing the human c.571_572insTT variant in the floorplate, no sprouting of vessels was observed, indicating that the base changes have a marked effect on the activity of VEGFC. CONCLUSIONS: We propose that the mutation in VEGFC is causative for the Milroy disease-like phenotype seen in this family. This is the first time a mutation in one of the ligands of VEGFR3 has been reported to cause primary lymphedema.
RATIONALE: Mutations in vascular endothelial growth factor (VEGF) receptor-3 (VEGFR3 or FLT4) cause Milroy disease, an autosomal dominant condition that presents with congenital lymphedema. Mutations in VEGFR3 are identified in only 70% of patients with classic Milroy disease, suggesting genetic heterogeneity. OBJECTIVE: To investigate the underlying cause in patients with clinical signs resembling Milroy disease in whom sequencing of the coding region of VEGFR3 did not reveal any pathogenic variation. METHODS AND RESULTS: Exome sequencing of 5 such patients was performed, and a novel frameshift variant, c.571_572insTT in VEGFC, a ligand for VEGFR3, was identified in 1 proband. The variant cosegregated with the affected status in the family. An assay to assess the biological function of VEGFC activity in vivo, by expressing humanVEGFC in the zebrafish floorplate was established. Forced expression of wild-type humanVEGFC in the floorplate of zebrafish embryos leads to excessive sprouting in neighboring vessels. However, when overexpressing the humanc.571_572insTT variant in the floorplate, no sprouting of vessels was observed, indicating that the base changes have a marked effect on the activity of VEGFC. CONCLUSIONS: We propose that the mutation in VEGFC is causative for the Milroy disease-like phenotype seen in this family. This is the first time a mutation in one of the ligands of VEGFR3 has been reported to cause primary lymphedema.
Authors: Matthew W Parker; Andrew D Linkugel; Hira Lal Goel; Tingting Wu; Arthur M Mercurio; Craig W Vander Kooi Journal: Structure Date: 2015-03-05 Impact factor: 5.006
Authors: Hung M Bui; David Enis; Marius R Robciuc; Harri J Nurmi; Jennifer Cohen; Mei Chen; Yiqing Yang; Veerpal Dhillon; Kathy Johnson; Hong Zhang; Robert Kirkpatrick; Elizabeth Traxler; Andrey Anisimov; Kari Alitalo; Mark L Kahn Journal: J Clin Invest Date: 2016-05-09 Impact factor: 14.808
Authors: Elisa Boscolo; Silvia Coma; Valerie L Luks; Arin K Greene; Michael Klagsbrun; Matthew L Warman; Joyce Bischoff Journal: Angiogenesis Date: 2014-11-26 Impact factor: 9.596
Authors: Masahiro Shin; Ira Male; Timothy J Beane; Jacques A Villefranc; Fatma O Kok; Lihua J Zhu; Nathan D Lawson Journal: Development Date: 2016-09-12 Impact factor: 6.868
Authors: Kelly L Betterman; Drew L Sutton; Genevieve A Secker; Jan Kazenwadel; Anna Oszmiana; Lillian Lim; Naoyuki Miura; Lydia Sorokin; Benjamin M Hogan; Mark L Kahn; Helen McNeill; Natasha L Harvey Journal: J Clin Invest Date: 2020-06-01 Impact factor: 14.808